Biotechnology company UniQure is preparing to submit an application to the U.S. Food and Drug Administration (FDA) seeking approval for its gene therapy aimed at treating Huntington's disease. The therapy, known as AMT-130, targets the underlying genetic cause of the debilitating neurodegenerative disorder. This move comes after a period of public discussion and debate between UniQure and FDA leadership concerning the clinical trial data supporting the therapy's efficacy and safety. The company has indicated it will proceed with its submission despite the previous disagreements, signaling confidence in its research and development. Huntington's disease is a progressive, inherited condition that leads to the breakdown of nerve cells in the brain, resulting in severe physical and cognitive decline. The absence of a cure makes the development of effective treatments a critical area of medical research. UniQure's proposed therapy represents a novel approach, utilizing gene therapy to potentially halt or slow the progression of the disease.